Synthesis of Peptide-Based Vaccines

  • Zhanna Potetinova
  • Gordon E. Willick
Part of the Advances in Experimental Medicine and Biology book series (volume 611)


Lipopeptides are potent and non-toxic adjuvants. Peptides by themselves are poor immunogens, even when incorporated in liposomes. For effective interaction with both the innate and adaptive immune responses, peptides must be conjugated with one of several known lipid moieties.

Tri- or dipalmitoyl-S-glyceryl-Cys-Ser-Ser, based on a bacterial lipoprotein, was found to be an effective adjuvant [1] that was later replaced by the more readily synthesized dipalmitoyl-Lys-Ser-Ser [2]. The purification of lipopeptides remains a problem, however, due to low aqueous solubility and the loss of resolution using traditional HPLC technology. Moreover, difficulties in their analysis hinder the use of such peptide-based vaccines in human clinical experiments. Purification of the unprotected peptides prior to conjugation of whatever lipid modification being used is highly desirable. Methods now available rely on exploitation of Cys residues for conjugation. Maleimide-based conjugation is...


Poor Immunogen HPLC Purity Native Chemical Ligation Bacterial Lipoprotein Kaiser Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Hoffmann, P., et al. Immunobiology 177, 158 (1988).CrossRefGoogle Scholar
  2. 2.
    Huang, W., et al. Mol. Immunol. 31, 1191 (1994).CrossRefGoogle Scholar
  3. 3.
    Roth, A., et al. Bioconjugate Chem. 15, 541 (2004).CrossRefGoogle Scholar
  4. 4.
    Tam, J.P., et al. Proc. Natl. Acad. Sci. USA 92, 12485 (1995).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Zhanna Potetinova
    • 1
  • Gordon E. Willick
    • 1
  1. 1.Institute for Biological SciencesNational Research CouncilOttawaCanada

Personalised recommendations